Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* advanced (stage IIIB/IV)non-small cell lung cancer;~* measurable disease;~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.~Exclusion Criteria:~* prior exposure to agents directed at the HER axis;~* prior chemotherapy or systemic anti-tumor therapy after advanced disease;~* unstable systemic disease;~* any other malignancy within last 5 years, except cured basal cell cancer of skin or cured cancer in situ of cervix;~* brain metastasis or spinal cord compression.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).